14 In addition, the processing of personal data in connection with clinical trials in the EU must comply with comprehensive data protection requirements imposed by EU’s General Data Protection Regulation, or EU GDPR. The EU GDPR, which took effe f ct on May 25, 2018, imposes stringent data protection requirements and provides for penalties for noncompliance that can include bans on processing personal data and fines of up to the greater of 20 million euros or four percent of worldwide annual revenues. The EU GDPR requires organizations to give detailed disclosures about how they collect, use and share personal data; under certain conditions, obtain explicit consent to process sensitive personal data, such as health or genetic information; contractua t lly require vendors to meet data protection requirements; maintain adequate data security measures; notify f regulators and affe f cted individuals of certain data breaches; meet extensive privacy governance and documentation requirements; and affo f rd individuals’ data protection rights, including their rights to access, correct and delete their personal data. European data protection laws, generally restrict the transfer f of personal data from Europe, including from the European Economic Area, the United Kingdom and Switzerland, to the U.S. and most other countries unless the parties to the transfer f have implemented specific f safeguards to protect the transfer f red personal data. Legal challenges, in the past and future, may be successful f in limiting the mechanisms availabl a e to transfer f personal data across national borders. The failure to comply with any of these laws or regulatory r requirements may result in legal and regulatory r actions. Depending on the circumstances, failure to meet applicable regulatory requirements can result in significant penalties, including administrative, civil, and criminal penalties, fines, imprisonment, disgorgement, inju n nctions, exclusion from participation in federal healthcare programs, integrity oversight and reporting obligations, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals or refusal to allow a firm to enter into suppl u y contracts, including government contracts. Any action against us for violation of these laws, even if we successful f ly defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affe f ct our business in an adverse way. U.S. Health l Care Refo e rm Changes in regulations, statut t es or the interpretation of existing regulations could impact our business in the future by requiring, for example: (1) changes to our manufac f turing arrangements; (2) additions or modifications to product labe a ling; (3) the recall or discontinuation of our products; or (4) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affe f ct the operation of our business. Further, the United States, there have been and continue to be a number of healthcare-related legislative initiatives that have significantly affe f cted the healthcare industry. r For example, on June 17, 2021 the U.S. Supr u eme Court dismissed a challenge on procedur d al grounds that argued the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress. Further, prior to the U.S. Supr u eme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period from Februa r ry 15, 2021 through May 15, 2021 for purpos r es of obtaining health insurance coverage through the ACA marketpl t ace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. In addition, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, R into law, which among other things, extends enhanced subs u idies for individuals purchasing health insurance coverage in ACA marketpl t aces through plan year 2025. The IRA R also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary r maximum out-of-pocket cost and creating a new manufac f turer discount program. It is unclear how any additional challenges and healthcare form measures of the Biden administration will impact the ACA and our business. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufac f turers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufact f ur t er patient programs, and reform government program reimbursement methodologies for drug r products. For example, in July 2021, the Biden administration released an executive order, “Promoting Competition in the American Economy,” with multiple provisions aimed at prescription drugs r . In response to Biden’s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug r Prices that outlines principles for drug r pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA, R among other things, (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs r and biologics covered under Medicare, and subj u ect drug r manufact f ur t ers to civil monetary penalties and a potential excise tax by offe f ring a price that is not equal to or less than the negotiated “maximum fair price” for such drugs r and biologics under the law, and (ii) imposes rebates with respect to certain drugs r and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that outpa t ce inflation. The IRA R permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions take effe f ct progressively starting in fiscal year 2023. On August 29, 2023, HHS announced the list of the first ten drugs r that will be subj u ect to price negotiations, although the Medicare drug r price negotiation program is currently subj u ect to legal challenges. It is currently unclear how the IRA R will be implemented but is likely to have a significant impact on the pharmaceutical industry. r In response to the Biden administration’s October 2022 executive order, on Februa r ry 14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs r , promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health